Protagonist Therapeutics, Inc. (PTGX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$98.85
Price Target
$116.75
Target Range
$108.00 — $121.00
Analyst Rating
Buy
Forward P/E30.6x
Trailing P/E-48.2x
Forward PEG—
Implied Growth+298.5%
Median Target$119.00
Analyst Spread11.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$108
+9.3%
Consensus
$117
+18.1%
Bull Case
$121
+22.4%
PTGX Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Protagonist Therapeutics, Inc. (PTGX) has a Wall Street consensus price target of $116.75, based on estimates from 26 covering analysts. With the stock currently trading at $98.85, this represents a potential upside of +18.1%. The company has a market capitalization of $6.36B.
Analyst price targets range from a low of $108.00 to a high of $121.00, representing a 11% spread in expectations. The median target of $119.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 25 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PTGX trades at a trailing P/E of -48.2x and forward P/E of 30.6x. Analysts expect EPS to grow +298.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+64.3%
Avg Forward P/E33.6x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $5.5B | $27.22 | $45.50 | +67.2% | Buy | — | 23 |
 KYMRKymera Therapeutics, Inc. | $6.9B | $84.63 | $117.06 | +38.3% | Buy | — | 26 |
 PRTAProthena Corporation plc | $567M | $10.53 | $19.00 | +80.4% | Buy | 42.7x | 28 |
 ACRSAclaris Therapeutics, Inc. | $586M | $4.86 | $10.00 | +105.8% | Buy | — | 16 |
 ARDXArdelyx, Inc. | $1.7B | $6.98 | $17.00 | +143.6% | Buy | — | 16 |
 IONSIonis Pharmaceuticals, Inc. | $12.6B | $76.02 | $107.27 | +41.1% | Buy | — | 32 |
 ALNYAlnylam Pharmaceuticals, Inc. | $39.5B | $295.91 | $445.67 | +50.6% | Buy | 44.2x | 52 |
 SRPTSarepta Therapeutics, Inc. | $2.2B | $20.80 | $24.63 | +18.4% | Buy | 6.9x | 54 |
 RAREUltragenyx Pharmaceutical Inc. | $2.6B | $26.13 | $51.50 | +97.1% | Buy | — | 33 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
Upside Potential Comparison
ARDXACRSRAREPRTAIMVTALNYIONSKYMRSee PTGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTGX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTGX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPTGX — Frequently Asked Questions
Quick answers to the most common questions about buying PTGX stock.
What is the PTGX stock price target for 2026?
Protagonist Therapeutics, Inc. (PTGX) has a consensus 12-month price target of $116.75, implying 18.1% upside from $98.85. The 26 analysts covering PTGX see moderate appreciation potential.
Is PTGX a buy, sell, or hold?
PTGX has a consensus rating of "Buy" based on 26 Wall Street analysts. The rating breakdown is predominantly bullish, with 25 Buy/Strong Buy ratings. The consensus 12-month price target of $116.75 implies 18.1% upside from current levels.
Is PTGX stock overvalued or undervalued?
PTGX trades at a forward P/E of 30.598x, representing a moderate valuation. With analysts targeting $116.75 (18.1% implied move), the stock appears reasonably valued with upside.
How high can PTGX stock go?
The most bullish Wall Street analyst has a price target of $121 for PTGX, while the most conservative target is $108. The consensus of $116.75 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover PTGX stock?
PTGX is heavily covered by Wall Street, with 26 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 25 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PTGX stock forecast?
The 12-month PTGX stock forecast based on 26 Wall Street analysts shows a consensus price target of $116.75, with estimates ranging from $108 (bear case) to $121 (bull case). The median consensus rating is "Buy".
What is PTGX's forward P/E ratio?
PTGX trades at a forward P/E ratio of 30.6x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy PTGX stock?
Wall Street analysts are optimistic on PTGX, with a "Buy" consensus rating and $116.75 price target (18.1% upside). 25 of 26 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PTGX price targets vary so much?
PTGX analyst price targets range from $108 to $121, a 11% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $116.75 consensus represents the middle ground.